Gilead Sciences
- All
- News
- Videos
-
25,000 Doses Of Remdesivir From Gilead Sciences Reach India
The third consignment consisting of 25000 doses of Remdesivir from American biopharmaceutical company Gilead Sciences reached India on Saturday.
-
India To Import 4,50,000 Vials Of Anti-Viral Drug Remdesivir: Centre Amid Shortage
The government of India has started importing anti-viral drug Remdesivir from other countries and the first consignment of 75,000 vials will reach India today amid the ongoing Covid pandemic, Union Ministry of Chemicals and Fertilisers has said.
-
US Firm To Expand Remdesivir Availability In India; Donate 4.5 Lakh Vials
US Drug firm Gilead Sciences said it is taking several steps to expand the availability of antiviral drug Remdesivir in India and will also be donating a minimum of 4.5 lakh vials of 'Veklury' to the Indian government.
-
WHO Says No Evidence Remdesivir Improves Survival, Gilead "Disappointed"
The World Health Organization recommended against using Gilead Sciences Inc.'s remdesivir to treat hospitalized Covid-19 patients less than a month after U.S. regulators granted the drug a speedy approval.
-
Nations Eyeing Gilead's Covid Drug Should Take Note Of Failed Trial: WHO
Health officials reviewing Gilead Science Inc's remdesivir against COVID-19 should consider all evidence, including a trial in which the medicine failed, before giving it the green light, the top WHO scientist said on Friday.
-
WHO Defends Data After Concluding Gilead's Remdesivir Flopped Covid Trial
A World Health Organization (WHO) trial that concluded Gilead Sciences Inc.'s remdesivir did not significantly help COVID-19 patients is reliable, a scientist who evaluated the data said on Friday, as the U.S. company criticized its methodology.
-
Remdesivir Didn't Cut Hospital Stay Or Mortality In Covid Patients: WHO
Gilead Sciences Inc's remdesivir had little or no effect on COVID-19 patients' length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) has found.
-
Gilead Seeks US Approval For Drug That Shortens Covid Recovery Time
Gilead Sciences Inc has filed an application with the U.S. Food and Drug Administration seeking full approval for remdesivir, its experimental COVID-19 drug currently used under emergency authorization, the drugmaker said on Monday.
-
Gilead Analysis Shows Remdesivir Reduced Coronavirus Death Risk
Gilead Sciences Inc said on Friday an analysis showed its antiviral remdesivir helped reduce the risk of death in severely ill COVID-19 patients, but cautioned that rigorous clinical trials were needed to confirm the benefit.
-
Remdesivir Reduces Risk Of Death In COVID-19 Patients, Says Gilead
Gilead Sciences Inc. said on Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill COVID-19 patients.
-
Mylan Pharma To Launch Remdesivir In India At Rs 4,800 Per 100 mg Vial
Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.
-
Gilead Prices COVID-19 Drug Remdesivir At $2,340 Per Patient In Developed Nations
Gilead Sciences Inc on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.
-
Astronomers Discover Two Super-Earths Orbiting a Star 11 Light-Years Away
Astronomers have discovered two super-Earths around a star Gilese 887 that is approximately 11 light-years away from our planet. The two exoplanets – a term used for planets outside our solar system – are called Gilese 887b and Gilese 887c, and the scientists claim that they could ‘potentially host life’.
-
US Group Raises Pricing Recommendation For Gilead's Remdesivir In COVID
Gilead Sciences Inc's antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, a U.S. drug pricing research group suggested on Wednesday, above its prior recommendation of around $4,500.
-
US Pharma Firm Gilead To Make 2 Million Courses Of Remdesivir By 2020 End
Gilead Sciences Inc is planning to make more than two million courses of its potential COVID-19 drug remdesivir by the end of the year and start trials of an easier-to-use inhaled version in August, the company said on Monday.
-
25,000 Doses Of Remdesivir From Gilead Sciences Reach India
The third consignment consisting of 25000 doses of Remdesivir from American biopharmaceutical company Gilead Sciences reached India on Saturday.
-
India To Import 4,50,000 Vials Of Anti-Viral Drug Remdesivir: Centre Amid Shortage
The government of India has started importing anti-viral drug Remdesivir from other countries and the first consignment of 75,000 vials will reach India today amid the ongoing Covid pandemic, Union Ministry of Chemicals and Fertilisers has said.
-
US Firm To Expand Remdesivir Availability In India; Donate 4.5 Lakh Vials
US Drug firm Gilead Sciences said it is taking several steps to expand the availability of antiviral drug Remdesivir in India and will also be donating a minimum of 4.5 lakh vials of 'Veklury' to the Indian government.
-
WHO Says No Evidence Remdesivir Improves Survival, Gilead "Disappointed"
The World Health Organization recommended against using Gilead Sciences Inc.'s remdesivir to treat hospitalized Covid-19 patients less than a month after U.S. regulators granted the drug a speedy approval.
-
Nations Eyeing Gilead's Covid Drug Should Take Note Of Failed Trial: WHO
Health officials reviewing Gilead Science Inc's remdesivir against COVID-19 should consider all evidence, including a trial in which the medicine failed, before giving it the green light, the top WHO scientist said on Friday.
-
WHO Defends Data After Concluding Gilead's Remdesivir Flopped Covid Trial
A World Health Organization (WHO) trial that concluded Gilead Sciences Inc.'s remdesivir did not significantly help COVID-19 patients is reliable, a scientist who evaluated the data said on Friday, as the U.S. company criticized its methodology.
-
Remdesivir Didn't Cut Hospital Stay Or Mortality In Covid Patients: WHO
Gilead Sciences Inc's remdesivir had little or no effect on COVID-19 patients' length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) has found.
-
Gilead Seeks US Approval For Drug That Shortens Covid Recovery Time
Gilead Sciences Inc has filed an application with the U.S. Food and Drug Administration seeking full approval for remdesivir, its experimental COVID-19 drug currently used under emergency authorization, the drugmaker said on Monday.
-
Gilead Analysis Shows Remdesivir Reduced Coronavirus Death Risk
Gilead Sciences Inc said on Friday an analysis showed its antiviral remdesivir helped reduce the risk of death in severely ill COVID-19 patients, but cautioned that rigorous clinical trials were needed to confirm the benefit.
-
Remdesivir Reduces Risk Of Death In COVID-19 Patients, Says Gilead
Gilead Sciences Inc. said on Friday additional data from a late-stage study showed its antiviral remdesivir reduced the risk of death and significantly improved the conditions of severely ill COVID-19 patients.
-
Mylan Pharma To Launch Remdesivir In India At Rs 4,800 Per 100 mg Vial
Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's COVID-19 treatment remdesivir in India this month at 4,800 rupees ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.
-
Gilead Prices COVID-19 Drug Remdesivir At $2,340 Per Patient In Developed Nations
Gilead Sciences Inc on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.
-
Astronomers Discover Two Super-Earths Orbiting a Star 11 Light-Years Away
Astronomers have discovered two super-Earths around a star Gilese 887 that is approximately 11 light-years away from our planet. The two exoplanets – a term used for planets outside our solar system – are called Gilese 887b and Gilese 887c, and the scientists claim that they could ‘potentially host life’.
-
US Group Raises Pricing Recommendation For Gilead's Remdesivir In COVID
Gilead Sciences Inc's antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, a U.S. drug pricing research group suggested on Wednesday, above its prior recommendation of around $4,500.
-
US Pharma Firm Gilead To Make 2 Million Courses Of Remdesivir By 2020 End
Gilead Sciences Inc is planning to make more than two million courses of its potential COVID-19 drug remdesivir by the end of the year and start trials of an easier-to-use inhaled version in August, the company said on Monday.
